Cryoport, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYRX research report →
Range $13.5 – $28
Price Chart
About the company
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process.
- CEO
- Jerrell W. Shelton
- IPO
- 2005
- Employees
- 688
- HQ
- Brentwood, TN, US
Get TickerSpark's AI analysis on CYRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $990.19M
- P/E
- -21.97
- PEG
- 0.13
- P/S
- 5.15
- P/B
- 2.05
- EV/EBITDA
- -130.67
- Div Yield
- 0.00%
- Gross Margin
- 46.91%
- Op Margin
- -20.00%
- Net Margin
- -20.88%
- ROE
- -8.15%
- ROIC
- -5.36%
Latest fiscal year · YoY change
- Revenue
- $176.18M-24.5%
- Gross Profit
- $83.05M-16.4%
- Op Income
- $-36,806,000
- Net Income
- $78.30M+178.6%
- EPS
- $1.40+163.3%
- OCF Growth
- +47.4%
- FCF Growth
- +16.4%
- Beta
- 1.89
- RSI (14)
- 57
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cryoport posted 14% revenue growth, turned adjusted EBITDA positive for a second straight quarter, and raised full-year revenue guidance on continued momentum in cell and gene therapy and MVE products.· November 5, 2026
- Revenue was $50.2 million, up 14% year over year; Life Sciences Services grew 18% and Life Sciences Products grew 8%.
- Adjusted EBITDA was positive for the second consecutive quarter at $1.1 million, improving $1.8 million year over year.
- The company ended Q3 supporting 23 commercial therapies and a record 788 clinical trials, up 43 from a year ago, with 99 in Phase III.
- Management raised full-year 2026 revenue guidance to $197 million to $199 million, citing broad-based strength and a prudent outlook.
- MVE demand was solid, especially in animal health and the Fusion freezer line, while China was described as stabilized but not a major growth driver.
Cryoport reported third-quarter revenue of $50.2 million, up 14% year over year. Life Sciences Services revenue increased 18% and represented 57% of total company revenue, while Life Sciences Products revenue grew 8%. Adjusted EBITDA was $1.1 million, the second straight positive quarter, and improved $1.8 million year over year. The company ended the quarter supporting 23 commercial therapies and a record 788 clinical trials, including 99 Phase III trials. Management raised full-year 2026 revenue guidance to $197 million to $199 million and said the midpoint implies about 12% growth year over year; they did not provide a specific Q4 revenue target beyond saying the range is prudent and there is upside potential.
Jerry Shelton said Cryoport had another strong quarter, driven by growing patient adoption of cell and gene therapies, expanding commercial therapy support, and solid demand across the business. He emphasized the company’s integrated supply chain platform, the progress toward profitability, and the benefits of new certifications and expanded capabilities in Paris and Santa Ana. His tone was confident and upbeat, but he repeatedly framed guidance conservatively.
Robert Stefanovich highlighted that guidance was raised after several quarters of strong revenue growth and bottom-line improvement, but he characterized the new range as prudent. He said the midpoint implies about 12% year-over-year growth and noted there is upside potential, while also explaining that some of the growth and margin benefit from new service capabilities will build over time as utilization increases. He also reiterated longer-term targets of 55% gross margin and 30% adjusted EBITDA, and said the company sees a path to more EBITDA margin expansion in 2027 and beyond.
Analysts pressed management on what was driving the higher guidance, whether Q4 would step up in services or products, and how much macro caution remained. Management said the guide is conservative, is based on current customers and recent momentum rather than new approvals, and that the new Q4 approvals are not really baked into the revenue outlook because launches take time to ramp. On pipeline timing, Mark Sawicki said four applications expected in 2026 were pushed into 2027, and confirmed the two upcoming approvals are Arcellx and Capricor, one in November and one in December.
The bull case is that Cryoport is seeing broad-based momentum in both services and products, with 20% growth in commercial cell and gene therapy revenue and a record clinical trial pipeline that keeps expanding. Management also described improved operating leverage, positive adjusted EBITDA, and a clear path to higher margins as new facilities and bioservice capabilities scale.
The main risks discussed were timing slippage in pipeline filings and approvals, with four applications pushed from 2026 into 2027, and management acknowledged that new approvals are not immediately reflected in revenue because they take time to ramp. They also described the guidance as intentionally conservative amid external uncertainty, and said China is stabilized but not a significant growth driver.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.8%
- Shares Outstanding
- 50.65M
- Float Shares
- 46.01M
of shares held by institutions
197 13F filers
Buy/sell ratio 0.60. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CYRX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 23 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Feb 28, 22 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Jan 13, 22 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Jan 31, 22 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Jan 14, 22 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Sep 21, 21 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Nov 24, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Nov 13, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Buy | Nov 17, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Buy | Nov 2, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Jul 14, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | May 7, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Feb 6, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Buy | Jan 13, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 3.95M | ▼ 264.16K |
| Cadian Capital Management, LP | 2.92M | ▼ 1.86M |
| Vanguard Group Inc | 2.91M | ▲ 47.92K |
| Morgan Stanley | 2.56M | ▲ 281.94K |
| Vanguard Capital Management LLC | 2.15M | ▼ 4.60K |
| Millennium Management LLC | 1.72M | ▼ 1.25M |
| Fred Alger Management, LLC | 1.55M | ▼ 154.09K |
| Geode Capital Management, LLC | 1.42M | ▲ 102.78K |
| Mak Capital One LLC | 1.28M | ▼ 145.91K |
| First Eagle Investment Management, LLC | 1.27M | ▼ 2.50K |
| State Street Corp | 1.07M | ▲ 23.77K |
| Dimensional Fund Advisors LP | 1.03M | ▲ 26.13K |
Held by 164 ETFs
Biggest fund positions in CYRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Sawicki Mark W | sell | 10,000 |
| Nov 9, 26 | HANCOCK DANIEL M | other | 20,549 |
| Nov 9, 26 | HANCOCK DANIEL M | other | 23,830 |
| Nov 9, 26 | HANCOCK DANIEL M | other | 30,000 |
| Nov 9, 26 | HANCOCK DANIEL M | sell | 74,379 |
| Nov 9, 26 | HANCOCK DANIEL M | other | 20,549 |
| Nov 9, 26 | HANCOCK DANIEL M | other | 30,000 |
| Nov 9, 26 | HANCOCK DANIEL M | other | 23,830 |
| Aug 11, 26 | SHELTON JERRELL | sell | 28,800 |
| Jun 11, 26 | ZECCHINI EDWARD J | other | 33,600 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CYRX coverage
Recent articles, reports, and earnings notes.
No research on CYRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYRX report →